These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 6897280)

  • 21. Inhibition of calmodulin-activated smooth-muscle myosin light-chain kinase by calmodulin-binding peptides and fluorescent (phosphodiesterase-activating) calmodulin derivatives.
    Török K; Cowley DJ; Brandmeier BD; Howell S; Aitken A; Trentham DR
    Biochemistry; 1998 Apr; 37(17):6188-98. PubMed ID: 9558358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity-structure relationship of calmodulin antagonists, Naphthalenesulfonamide derivatives.
    Hidaka H; Asano M; Tanaka T
    Mol Pharmacol; 1981 Nov; 20(3):571-8. PubMed ID: 7329399
    [No Abstract]   [Full Text] [Related]  

  • 23. Divergent pharmacological effects of three calmodulin antagonists, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), chlorpromazine and calmidazolium, on isometric tension development and myosin light chain phosphorylation in intact bovine tracheal smooth muscle.
    Asano M
    J Pharmacol Exp Ther; 1989 Nov; 251(2):764-73. PubMed ID: 2810127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of human platelet secretion and of Ca2+, calmodulin-dependent protein phosphorylation by the antiallergic agent GMCHA.
    Tanaka T; Saitoh M; Ito M; Shin T; Naka M; Endo K; Hidaka H
    Biochem Pharmacol; 1988 Jul; 37(13):2537-42. PubMed ID: 3390216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphorylation of calmodulin alters its potency as an activator of target enzymes.
    Quadroni M; L'Hostis EL; Corti C; Myagkikh I; Durussel I; Cox J; James P; Carafoli E
    Biochemistry; 1998 May; 37(18):6523-32. PubMed ID: 9572870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ca2+/Calmodulin-dependent protein kinase II phosphorylation of ryanodine receptor does affect calcium sparks in mouse ventricular myocytes.
    Guo T; Zhang T; Mestril R; Bers DM
    Circ Res; 2006 Aug; 99(4):398-406. PubMed ID: 16840718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ca2+-calmodulin tubulin kinase system and its role in mediating the Ca2+ signal in brain.
    Delorenzo RJ; Gonzalez B; Goldenring J; Bowling A; Jacobson R
    Prog Brain Res; 1982; 56():257-86. PubMed ID: 6298873
    [No Abstract]   [Full Text] [Related]  

  • 28. Stimulatory effect of calmodulin antagonists on phospholipid base-exchange reactions in rabbit platelet membranes.
    Morikawa S; Taniguchi S; Mori H; Fujii K; Kumada K; Fujiwara M; Fujiwara M
    Biochem Pharmacol; 1986 Dec; 35(24):4473-7. PubMed ID: 3098251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of calmodulin antagonists and cytochalasins on proliferation and differentiation of human promyelocytic leukemia cell line HL-60.
    Matsui T; Nakao Y; Kobayashi N; Koizumi T; Nakagawa T; Kishihara M; Fujita T
    Cancer Res; 1985 Jan; 45(1):311-6. PubMed ID: 3855282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Basic protein in brain myelin is phosphorylated by endogenous phospholipid-sensitive Ca2+-dependent protein kinase.
    Turner RS; Chou CH; Kibler RF; Kuo JF
    J Neurochem; 1982 Nov; 39(5):1397-404. PubMed ID: 6181205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor effect of a calmodulin antagonist on the growth of solid sarcoma-180.
    Ito H; Hidaka H
    Cancer Lett; 1983 Jun; 19(2):215-20. PubMed ID: 6883309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calmodulin antagonists enhance calcium binding to calmodulin.
    Inagaki M; Tanaka T; Hidaka H
    Pharmacology; 1983; 27(3):125-9. PubMed ID: 6622516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The binding of the calcium channel blocker, bepridil, to calmodulin.
    Itoh H; Tanaka T; Mitani Y; Hidaka H
    Biochem Pharmacol; 1986 Jan; 35(2):217-20. PubMed ID: 3484629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polyamines inhibit phospholipid-sensitive and calmodulin-sensitive Ca2+-dependent protein kinases.
    Qi DF; Schatzman RC; Mazzei GJ; Turner RS; Raynor RL; Liao S; Kuo JF
    Biochem J; 1983 Aug; 213(2):281-8. PubMed ID: 6615435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antagonists of calcium fluxes and calmodulin block activation of the p21-activated protein kinases in neutrophils.
    Lian JP; Crossley L; Zhan Q; Huang R; Coffer P; Toker A; Robinson D; Badwey JA
    J Immunol; 2001 Feb; 166(4):2643-50. PubMed ID: 11160327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcium and calmodulin antagonists binding to calmodulin and relaxation of coronary segments.
    Johnson JD; Fugman DA
    J Pharmacol Exp Ther; 1983 Aug; 226(2):330-4. PubMed ID: 6875846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct interaction of calmodulin antagonists with Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterase.
    Itoh H; Hidaka H
    J Biochem; 1984 Dec; 96(6):1721-6. PubMed ID: 6099352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein kinase C--catalyzed calponin phosphorylation in swine carotid arterial homogenate.
    Rokolya A; Walsh MP; Singer HA; Moreland RS
    J Cell Physiol; 1998 Sep; 176(3):545-52. PubMed ID: 9699507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible involvement of calmodulin-dependent kinases in Ca(2+)-dependent enhancement of [3H]5-hydroxytryptamine uptake in rat cortex.
    Yura A; Kiuchi Y; Uchikawa T; Uchida J; Yamazaki K; Oguchi K
    Brain Res; 1996 Oct; 738(1):96-102. PubMed ID: 8949931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ca2+-calmodulin-dependent phosphorylation and platelet secretion.
    Nishikawa M; Tanaka T; Hidaka H
    Nature; 1980 Oct; 287(5785):863-5. PubMed ID: 7432502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.